Veeraraghavan Gayathri

Dr. Veeraraghavan Gayathri

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Heliyon
Verified
Journal Article
Open access
KGK. Gayathri
K. Gayathri
AAAbhinand. P A
Abhinand. P A
VGVeeraraghavan Gayathri
Veeraraghavan Gayathri
VLV. Prasanna Lakshmi
V. Prasanna Lakshmi
DCD. Chamundeeswari
D. Chamundeeswari
NMN. Malathi
N. Malathi
Oral submucous fibrosis (OSMF) is a potentially malignant disorder with no permanent cure that affects the quality of life due to trismus. Computational pharmacology has accelerated the discovery of drug candidates for the treatment of incurable diseases. The present study aimed to screen the compounds of the miracle herb Centella asiatica with drug-likeness properties based on the absorption, distribution, metabolism, and excretion (ADME) properties. The pharmacological actions of these screened compounds against OSMF were identified by network pharmacology, gene ontology, pathway enrichment analysis, molecular docking, and simulation. Fifteen drug-like ligands were identified after virtual screening viz; asiatic acid, kaempferol, quercetin, luteolin, apigenin, bayogenin, gallic acid, isothankunic acid, madecassic acid, madasiatic acid, arjunolic acid, terminolic acid, catechin, epicatechin, and nobiletin. 850 potential targets were predicted for the ligands, which were analyzed against 354 proteins associated with OSMF. Compound pathway analysis and disease pathway analysis identified 53 common proteins. The GO enrichment analysis identified 472 biological process terms, 76 molecular function terms, and 44 cellular component terms. Pathway enrichment analysis predicted 142 KEGG pathways, 35 Biocarta pathways, and 236 Reactome pathways for the target proteins. The analysis revealed that the herb targets crucial events of fibrosis such as inflammation, oxidative stress, apoptosis, collagen deposition, and epithelial-mesenchymal transition. The common 53 proteins were used for protein-protein interaction (PPI) network analysis, which revealed 4 key proteins interacting with the phytocompounds viz; transforming growth factor-β1 (TGF-β1), mothers against decapentaplegic-3 (SMAD-3), mitogen-activated protein kinase-1 (MAPK-1) and proto-oncogene tyrosine-protein kinase (SRC). Molecular docking revealed that all ligands had a good binding affinity to the target proteins. Bayogenin had the highest binding affinity towards MAPK-1 (−9.7 kcal/mol), followed by isothankunic acid towards SRC protein (−9.3 kcal/mol). Madasiatic acid had the highest binding affinity to SMAD-3 (−7.6 kcal/mol) and TGF-β1 (−7.1 kcal/mol). Molecular dynamics simulation demonstrated stable ligand protein interactions of bayogenin and MAPK complex, isothankunic acid and SRC complex. This in silico study is the first to identify potential phytochemicals present in Centella asiatica and their target molecules, which might be responsible for reversing OSMF.

11 December 2025 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
ADArghadip Das
Arghadip Das
NRNarmadha Chinnadurai Rajeswari
Narmadha Chinnadurai Rajeswari
PPPriyadharshini Palani
Priyadharshini Palani
NMNavaneedhakrishnan Manigandan
Navaneedhakrishnan Manigandan
SKSujatha Kuppuswamy
Sujatha Kuppuswamy
RSRaman Lakshmi Sundaram
Raman Lakshmi Sundaram
Background: Type 2 diabetes mellitus (T2DM) remains a global health burden characterized by insulin resistance, persistent hyperglycaemia, and chronic inflammation. Although single-target therapies effectively reduce glucose levels, they seldom address oxidative stress or adipocyte dysfunction. Polyherbal formulations (PHFs) harness synergistic phytochemicals for multimodal intervention; however, many lack mechanistic transparency owing to excessive inclusion of diverse botanical bioactives, suffer from non-standardized composition, and underexplore volatile antidiabetic constituents. Confronting these challenges, we developed Gluco Balance V (GB5), a cold-percolated ethanolic extract comprising equal proportions of bio-effective parts of Asparagus racemosus , Cyperus rotundus , Tinospora cordifolia , Terminalia arjuna , and Mimosa pudica . These botanicals were selected for complementary antidiabetic, antioxidant, and adiporegulatory activities documented in preclinical and clinical settings, indicating balanced, synergistic, and safe bioactivity. Methods: GB5’s phytochemical composition was standardized using gas chromatography–mass spectrometry (GC–MS) fingerprinting. In vitro assays assessed 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO) scavenging capacity, inhibition of carbohydrate-digesting enzymes (α-amylase, α-glucosidase), enzyme kinetics, and effects on glucose uptake (GU) and lipid accumulation (LA) in yeast and 3T3-L1 adipocytes. Computational network pharmacology, molecular docking, and pharmacokinetic analyses elucidated molecular targets and bioavailability. Statistical analyses employed robust dose-response modelling, analysis of variance with Dunnett’s T3 test, and t-tests with false discovery rate correction. Results: GC–MS identified 21 bioactive compounds, including phytol, fatty acids, and sterols, driving GB5’s therapeutic synergy. GB5 showed robust antioxidant activity (DPPH and NO; half-maximal inhibitory concentration (IC 50 ) 88.6 and 74.8 µg/mL) and mixed-type inhibition of α-amylase and α-glucosidase (IC 50 71.6 and 174 µg/mL). At sub-inhibitory doses, it outperformed ascorbic acid (ASA) and acarbose. In 3T3-L1 adipocytes, GB5 increased GU by 32.3% at 2.0 mg/mL, comparable to rosiglitazone, and reduced lipid accumulation by 18.6% (90% effective concentration (EC 90 ) 0.742 mg/mL). Network pharmacology and molecular docking implicated peroxisome proliferator-activated receptor gamma (PPARγ), protein tyrosine phosphatase 1B (PTP1B), cyclooxygenase-2 (COX-2), and advanced glycation end-products–receptor for advanced glycation end-products (AGE–RAGE) pathways with 9,12-octadecadienoic acid and cholestan-3-ol, 2-methylene-, (3β,5α)- as key associates. Conclusions: GB5’s multi-targeted efficacy against hyperglycaemia, oxidative stress, and adipocyte dysfunction positions it as a promising complementary therapy for T2DM, meriting further in vivo evaluation. Graphical


12 February 2026 in International Journal of Basic and Applied Sciences
Verified
Journal Article
Open access
PDF file
TSThiagarajan Sowmiya
Thiagarajan Sowmiya
EBEmmanuel Bhaskar
Emmanuel Bhaskar
VGVeeraraghavan Gayathri
Veeraraghavan Gayathri
PMParthasarathy Mohanalakshmi
Parthasarathy Mohanalakshmi
SSSanthi Silambanan
Santhi Silambanan
Purpose:‎ The gastrointestinal tract in humans is composed of various microorganisms including bacteria, ‎viruses, archaea, protozoa, and fungi. The interactions between gut and the microorganisms are ‎crucial for the processes such as digestion, nutrient absorption, immune function, and metabolic ‎regulation. Altered gut microbiota called dysbiosis, has been linked to the development and ‎progression of various non-communicable diseases. This review has been aimed to address the ‎alterations of gut microbiota in various non-communicable diseases.‎ Methods:‎ A thorough literature search was conducted in PubMed, Embase, Web of Science, Scopus, and ‎Google Scholar between January 2015 and December 2024 to identify studies examining the ‎impact of gut microbiota in metabolic diseases. The search utilized keywords such as gut ‎microbiota, gut dysbiosis, and altered microbiota in non-communicable diseases. The studies ‎included were full research articles and studies published in English. In this comprehensive ‎review, we explored the complex interplay between the gut microbiota and human health, ‎focusing on its role in common metabolic disorders such as obesity, metabolic dysfunction-‎associated fatty liver disease, type 2 diabetes mellitus, cardiovascular diseases, autoimmune ‎diseases, mental disorders, and cancer. Studies involving animal models, and cell lines and ‎reviews were excluded.‎ Conclusions: ‎The altered gut microbiota is involved in the initiation and progression of various non-‎communicable diseases. The dysbiosis not only aggravates the disease, but also causes ‎refractoriness to the management of the disease. Hence, it is better to identify the causes of ‎dysbiosis to control the harmful bacteria and to bring relief to the individuals with common con-‎communicable diseases‎.

8 May 2025 in Fitoterapia
Verified
Journal Article
Closed access
ADArghadip Das
Arghadip Das
VGVeeraraghavan Gayathri
Veeraraghavan Gayathri
SVSweatha Vijayakumar
Sweatha Vijayakumar
GBGanesh Babu
Ganesh Babu
STShonam Tamrakar
Shonam Tamrakar

9 June 2026 in Annals of Neurosciences
Verified
Journal Article
Open access
STShonam Tamrakar
Shonam Tamrakar
VGVeeraraghavan Gayathri
Veeraraghavan Gayathri
NPNatesan Pazhanivel
Natesan Pazhanivel
SKSuvarna Kantipudi
Suvarna Kantipudi
Background: Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental disorder. Numerous environmental risk factors have been implicated in the development of ASD in human cases, suggesting that multiple aetiological agents may contribute to developing an ASD rodent model. In this study, we have investigated the pathobiological processes and outcomes in a novel rat model of ASD that incorporates clinically relevant prenatal and perinatal insults. Specifically, a gamma-aminobutyric acid modulator, valproic acid (VPA), used for perinatal insults, and postnatal hypoxia was combined to understand the critical stages of brain development in rat pups and to explore potential causal mechanisms underlying ASD. Purpose: To develop the robust animal model for ASD using VPA and hypoxia as causative agents in combination to test other efficacious medicines for ASD in future. Method: A total of 16 female and 4 male Wistar rats were selected for mating, and the delivered pups were used for the study. The pregnant female animals were divided into four groups: G1: normal control group, G2: VPA group—received a single injection of VPA intraperitoneal (i.p.) on gestational day (GD) 12.5, G3: hypoxia group, rat pups were subjected to postnatal hypoxia, G4: VPA + hypoxia group, pregnant females received VPA (i.p. on GD 12.5), followed by normal delivery, after which the pups were subjected to postnatal hypoxia. Neurodevelopmental reflex tests, neurobehavioural assessments (open field test and Morris water maze) and three-chamber social interaction tests were conducted on the rat pups. Histopathological evaluation of the pups’ brains was performed. Results: The VPA, hypoxia and combined VPA + hypoxia groups exhibited significant neurobehavioural alterations, with marked delays in neurodevelopmental reflexes compared to the normal control group. Histopathological examination of the brain revealed a reduction in Purkinje cells within the Purkinje cell layer, along with extensive neuronal degeneration. The severity of both neurobehavioural deficits and histopathological abnormalities was greatest in the combined VPA + hypoxia group compared to the other experimental groups. Conclusions: These findings suggest that the combination of prenatal VPA exposure and postnatal hypoxia, representing pre- and perinatal insults, induces ASD-like conditions in rat pups that closely resemble the clinical behaviour features and redox imbalance of human ASD. Thus, this combined model could serve as a potential animal model for ASD and could be used for screening pharmacological agents aimed at treating and managing ASD.